In low-grade glioma of pilocytic astrocytoma, the recurrent cases always face difficulty in readopt chemotherapies, while targeting CD133-positive CSCs can significantly improve chemotherapeutic efficacy [143]. The gene discussed is PROM1; the disease is pilocytic astrocytoma.